Patents by Inventor Carol Carter
Carol Carter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11369622Abstract: A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex. The associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.Type: GrantFiled: August 5, 2020Date of Patent: June 28, 2022Assignees: Northwestern University, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Jonathan Leis, Carol Carter
-
Publication number: 20200368258Abstract: A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex. The associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.Type: ApplicationFiled: August 5, 2020Publication date: November 26, 2020Applicants: Northwestern University, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Jonathan Leis, Carol Carter
-
Patent number: 10765687Abstract: A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex. The associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.Type: GrantFiled: March 22, 2019Date of Patent: September 8, 2020Assignees: Northwestern University, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Jonathan Leis, Carol Carter
-
Publication number: 20200038388Abstract: The present invention provides a method of inhibiting release of a virus from a cell, comprising contacting the cell with a compound that binds an ubiquitin E2 variant (UEV) domain of a cellular polypeptide, or fragment thereof, with an affinity sufficient to inhibit or disrupt the binding of the cellular polypeptide, or fragment thereof, to ubiquitin.Type: ApplicationFiled: October 30, 2017Publication date: February 6, 2020Applicants: The Research Foundation for the State University of New York, THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicInventors: Carol Carter, Lorna Erlich, Nico Tjandra, Madeleine Davison
-
Publication number: 20190209589Abstract: A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex. The associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.Type: ApplicationFiled: March 22, 2019Publication date: July 11, 2019Applicants: Northwestern University, THE RESEARCH FOUNDATION FOR THE STATE OF UNIVERSITY OF NEW YORKInventors: Jonathan Leis, Carol Carter
-
Patent number: 10300080Abstract: A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex. The associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.Type: GrantFiled: November 10, 2015Date of Patent: May 28, 2019Assignees: Northwestern University, The Research Foundation for the State UniversityInventors: Jonathan Leis, Carol Carter
-
Publication number: 20170095485Abstract: A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex. The associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.Type: ApplicationFiled: November 10, 2015Publication date: April 6, 2017Inventors: Jonathan Leis, Carol Carter
-
Publication number: 20140179637Abstract: A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex. The associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.Type: ApplicationFiled: December 21, 2013Publication date: June 26, 2014Applicants: The Research Foundation for The State University of New York, Northwestern UniversityInventors: Jonathan Leis, Carol Carter
-
Patent number: 7494767Abstract: The present invention provides methods for identifying peptides in a mammalian. Tsg101 protein that binds to the PTAPP (SEQ ID NO: 3) motif or L domain of human immunodeficiency virus type I (HIV-1). Such peptides can be used to inhibit Tsg101-HIV Gag binding, and is therefore effective in reducing HIV particle production. The invention also provides the peptides identified by the method of the invention and to method of using such peptides for treating HIV infection.Type: GrantFiled: May 21, 2002Date of Patent: February 24, 2009Assignee: Functional Genetics, Inc.Inventors: Carol Carter, Arthur Goff, Lorna Ehrlich, Stanley N. Cohen
-
Publication number: 20050287525Abstract: The present invention provides methods for identifying peptides in a mammalian. Tsg101 protein that binds to the PTAPP motif or L domain of human immunodeficiency virus type I (HIV-1). Such peptides can be used to inhibit Tsg101-HIV Gag binding, and is therefore effective in reducing HIV particle production. The invention also provides the peptides identified by the method of the invention and to method of using such peptides for treating HIV infection.Type: ApplicationFiled: May 21, 2002Publication date: December 29, 2005Inventors: Carol Carter, Arthur Goff, Lorna Ehrlich, Stanley Cohen
-
Publication number: 20050176942Abstract: Bites from Amblyomma americanum, a hard tick, have been associated with a Lyme disease-like illness in the southeastern and south-central United States. Present in 2% of ticks collected in four states were uncultivable spirochetes. Through use of the polymerase chain reaction, partial sequences of the flagellin and 16s rRNA genes of microorganisms from Texas and New Jersey were obtained. The sequences showed that the spirochete was a Borrelia sp. but distinct from other known members of this genus, including B. burgdorferi, the agent of Lyme disease. Species-specific differences in the sequences of the flagellin protein, the flagellin gene and the 16s rRNA gene between the new Borrelia species and previously known species provide compositions and methods for assay for determining the presence of this new spirochete, or for providing evidence of past or present infection by this spirochete in animal reservoirs and humans.Type: ApplicationFiled: July 14, 2003Publication date: August 11, 2005Inventors: Alan Barbour, Carol Carter
-
Publication number: 20050009745Abstract: The present invention provides methods for identifying peptides in a mammalian. Tsg101 protein that binds to the PTAPP motif or L domain of human immunodeficiency virus type I (HIV-1). Such peptides can be used to inhibit Tsg101-HIV Gag binding, and is therefore effective in reducing HIV particle production. The invention also provides the peptides identified by the method of the invention and to method of using such peptides for treating HIV infection.Type: ApplicationFiled: September 18, 2003Publication date: January 13, 2005Inventors: Carol Carter, Arthur Goff, Lorna Ehrlich, Stanley Cohen
-
Patent number: 6617441Abstract: Bites from Amblyomma americanum, a hard tick, have been associated with a Lyme disease-like illness in the southeastern and south-central United States. Present in 2% of ticks collected in four states were uncultivable spirochetes. Through use of the polymerase chain reaction, partial sequences of the flagellin and 16s rRNA genes of microorganisms from Texas and New Jersey were obtained. The sequences showed that the spirochete was a Borrelia sp. but distinct from other known members of this genus, including B. burgdorferi, the agent of Lyme disease. Species-specific differences in the sequences of the flagellin protein, the flagellin gene and the 16s rRNA gene between the new Borrelia species and previously known species provide compositions and methods for assay for determining the presence of this new spirochete, or for providing evidence of past or present infection by this spirochete in animal reservoirs and humans.Type: GrantFiled: March 24, 1999Date of Patent: September 9, 2003Assignee: Board of Regents University of TexasInventors: Alan G. Barbour, Carol Carter
-
Patent number: 5932220Abstract: Bites from Amblyomma americanum, a hard tick, have been associated with a Lyme disease-like illness in the southeastern and south-central United States. Present in 2% of ticks collected in four states were uncultivable spirochetes. Through use of the polymerase chain reaction, partial sequences of the flagellin and 16s rRNA genes of microorganisms from Texas and New Jersey were obtained. The sequences showed that the spirochete was a Borrelia sp. but distinct from other known members of this genus, including B. burgdorferi, the agent of Lyme disease. Species-specific differences in the sequences of the flagellin protein, the flagellin gene and the 16s rRNA gene between the new Borrelia species and previously known species provide compositions and methods for assay for determining the presence of this new spirochete, or for providing evidence of past or present infection by this spirochete in animal reservoirs and humans.Type: GrantFiled: May 8, 1995Date of Patent: August 3, 1999Assignee: Board of Regents University of Texas SystemInventors: Alan G. Barbour, Carol Carter